Selpercatinib

Selpercatinib is a targeted cancer medication designed to specifically block a faulty protein called RET, which can drive the growth of certain cancers, including lung and thyroid cancers. By inhibiting RET, selpercatinib can slow or stop cancer progression. It is usually used for patients whose tumors have confirmed RET gene changes, providing a more precise treatment option. The drug is taken orally and is often well-tolerated, though side effects can occur. Overall, selpercatinib represents an advanced approach to personalized cancer therapy, aiming to improve outcomes for patients with RET-driven cancers.